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ronchodilators are routinely administered in pulmonary function laboratories to determine whether the obstructive ventilatory disturbance is reversible and even whether a normal individual shows a significant response to the drug. 1 The reversibility of bronchial obstruction is one of the criteria applied to the diagnosis of asthma, 2 and many clinical studies have used the parameter as a criterion for the selection of asthmatic patients. In adults, the FEV 1 is the best single spirometric parameter for the assessment of alterations in the degree of bronchial obstruction. 3 Measurement of plethysmographic variables as part of a bronchodilator test can provide additional information in selected patient groups. 4, 5 In practice, alterations in resistance and conductance are apparently more sensitive than spirometry in the characterization of changes in airway caliber. 6, 7 Depending on the clinical situation, the execution of both tests is recommended.
The determination of a cutoff value (ie, the level at which the bronchodilator response can be considered positive) is arbitrary. However, because variations in pulmonary function parameters have been found to be continuous and unimodal, a positive response can be determined by administering a placebo to individuals with airway obstruction. Based on this information, the upper limit of the confidence interval can be calculated, and values above this limit can be considered to indicate true functional improvement after bronchodilator treatment. 8 The criteria currently used for the classification of the bronchodilator response have been determined in adult populations. However, data regarding objective measures for the determination of the bronchodilator response in children are scarce or absent depending on which functional parameters are studied. In view of the importance and relevance of investigating the bronchodilator response in patients with asthma, the present study was carried out with the following specific objectives: (1) to establish a cutoff for variations in spirometric parameters indicating a positive bronchodilator response in children and adolescents with asthma, and (2) to compare the criterion of the bronchodilator response obtained for this population with that standardized by the American Thoracic Society (ATS).
Materials and Methods
Sixty patients with a clinical diagnosis of asthma 9 followed up at the Pneumology Unit, Instituto da Criança and the outpatient clinic of the Center of Asthma Care and Research, University Hospital, University of São Paulo Medical School participated in the study. Table 1 summarizes the clinical characteristics of the patients. The severity of asthma was classified according to the International Consensus on the Diagnosis and Management of Asthma. 2, 9 Pulmonary function tests were performed as part of the routine ambulatory assessment, and bronchodilators were withdrawn at least 12 h before the examination. Patients who had never undergone spirometry were properly instructed and performed the definitive test on a subsequent date. Exclusion criteria were the suspicion or confirmation of any other base disease or complications, as well as exacerbation of asthma within 4 weeks prior to evaluation and inadequate execution of the FVC maneuver. All patients were living in São Paulo urban area and were nonsmokers. We do not have information about exposure to tobacco smoke. Although the patients came from low-income families, they had height and weight in normal range. Previous studies 22, 24 about the nutritional status of our patients showed mild growth impairment only in patients with cystic fibrosis.
The pulmonary function tests were always performed in the morning by the same examiner following international recommendations. 10, 11 A bell spirometer (GS; Warren Collins; Braintree, MA) and plethysmograph (BP/PLUS; Warren Collins) were used. The results are reported as absolute values and as percentage of predicted values for height, sex, and age based on the equations of Polgar and Promadhat 12 and Polgar and Weng. 13 The examination was carried out in three steps: at baseline, 10 min after the administration of placebo, and again 15 min after inhalation of 400 g salbutamol spray (Aerolin; GlaxoWellcome SA; Aranda de Duero, Spain) administered with the help of a spacer (Aerochamber; Trudell Medical International; London, ON, Canada). Placebo administration consisted of the same inhalation procedure, but the drug flask was closed with plastic film, and therefore there was no drug delivery to the patient.
Distribution of the variations of functional parameters after placebo administration was analyzed by calculating the mean, SD, and percentiles for each parameter. The variations in FEV 1 expressed as percentage compared with baseline and percentage of the predicted values were calculated using following formulas, respectively: (FEV after placebo Ϫ FEV 1 before placebo) Ϭ FEV 1 before placebo and (FEV 1 after placebo Ϫ FEV 1 before placebo) Ϭ FEV 1 percentage of predicted. The Wilcoxon test was used to compare the variations after placebo between different age groups. 14 The patients were classified according to the severity of asthma as mild (mild intermittent plus mild persistent), moderate, and severe asthmatics. The Fisher exact test was used to compare variations after the placebo between the two groups. 14 To determine the influence of age and severity of asthma on the bronchodilator response, multivariate repeated measures analysis was used 15 ; p Ͻ 0.05 was considered significant.
Agreement between the bronchodilator response criterion established by the ATS, and the criterion obtained in the present study was determined with the McNemar test (p Ͻ 0.05 indicates the absence of agreement) and the index. 14 The Ethics Committee of University Hospital, University of São Paulo Medical School approved the study, and the patients or responsible persons signed a free informed consent form to participate.
Results
Only the following functional parameters considered of interest for the interpretation of the bronchodilator response were analyzed: FVC, FEV 1 , forced expiratory flow measured between 25% and 75% of FVC (FEF 25-75% ), specific airway conductance (sGaw), airway resistance (Raw), and residual volume (RV). The results of the pulmonary function tests performed at baseline, after placebo and bronchodilator administration, and distribution in the variations (⌬) of these parameters after placebo administration are shown in Tables 2, 3 . Depending on the pulmonary function parameter, the 95th or 5th percentiles were used as the respective cutoff value, indicating a positive bronchodilator response.
The cutoff values established were 265 mL, 14.2% and 10% FEV 1 expressed as absolute volume, percentage compared with baseline and percentage of the predicted values, respectively, and 55% sGaw expressed as percentage compared with baseline. The variations in FEF 25-75% observed did not show a normal distribution, thus impairing the same interpretation as used for the variation in the other parameters.
The behavior of the pulmonary function parameters after bronchodilator administration is shown in Table 4 . Thirty-six patients (60%) had a positive response when applying the criterion established by the ATS 10 for the classification of bronchodilator responses, ie, an increase in FEV 1 or FVC of 200 mL and 12% compared with baseline. No isolated or significant increase in FVC was observed, ie, all patients with a significant bronchodilator response could be identified, considering alterations in FEV 1 only. Forty-eight patients (80%) showed variations in sGaw Ͼ 55% and were thus classified as bronchodilator responders. Variations in FVC, FEF 25-75% , and RV were unsuitable and inadequate for patient classification.
Discussion
In this young asthmatic population, distribution of variations of pulmonary function parameters was determined after placebo inhalation. The 95th percentile was adopted as the cutoff value, indicating a Data regarding spontaneous functional variability among children are scarce, and any cutoff chosen to distinguish "normal" from "abnormal" variations is arbitrary. Empirical determination of percentile distributions permits a clinically more useful and appropriate interpretation in terms of the functional assessment of children or adolescents in the rapid phase of growth. 16 Placebo inhalation by the population studied permitted the determination of the expected variability in the different functional parameters analyzed. Except for FEF 25-75% , all parameters showed a variation in normal and unimodal distribution when establishing the 95th or 5th percentiles as cutoffs.
Only asthmatic patients were included in the present study, and all subjects sequentially participated in the placebo and bronchodilator phase. In their classical study, Sourk and Nugent 17 analyzed similar data obtained for 79 adults, but only 42 patients inhaled placebo, and this subgroup did not only include asthmatics but also patients with COPD, smokers, and individuals with chronic cough. In this respect, it does not seem adequate to apply a bronchodilator response criterion, established on the basis of results of pulmonary function tests obtained for patients with COPD, to patients with asthma. 18 Similarly, children and adolescents with asthma may show a greater bronchodilator response than asthmatic adults simply due to the time of evolution of the disease. The duration of asthma is related to the degree of airflow limitation and its reversibility, 19 and early institution of antiinflammatory treatment prevents this irreversible alteration of pulmonary function. 20 The present series mainly consisted of patients with moderate persistent asthma (75%). This finding can be explained by the fact that the hospital represents a referral center for severe cases of respiratory disease. The probability of a positive bronchodilator response is higher in these patients 21 because they show functional signs of obstruction. However, inflammation might strongly contribute to airway obstruction, a condition that is not exclusively reversed by the action of bronchodilators. 22 It was not possible to confirm or rule out the hypothesis that the severity of the disease might have interfered with the cutoff established for a significant bronchodilator response because only 15 patients were classified as having mild asthma (intermittent and persistent). Possible age-related differences in variations of studied parameters were not observed when the patients were classified according to age Ͼ 12 years or Ͻ 12 years, a value corresponding to the median age of the population studied.
The FEV 1 cutoff values obtained are similar to those reported in the literature. 10, 17, 23 The cutoff for ⌬FEV 1 percentage of predicted was 6.8% in children Ͼ 12 years old, in agreement with values proposed by Pereira 24 for adult Brazilian patients with obstructive disease. Agreement between the criteria obtained and those proposed by the ATS was observed when the bronchodilator response was established on the basis of variations in FEV 1 expressed as absolute volume and percentage of the predicted value, as demonstrated by the relatively high indexes (Ͼ 0.60). Despite the agreement between criteria, conceptual or methodologic differences should be taken into account. Routine application of the ATS criterion might lead to inadequate classification of patients with peculiar characteristics, such as asthmatic children.
Controversies continue to exist regarding the cutoff indicating a positive bronchodilator response, in part because no consensus exists on how the bronchodilator response should be expressed. 25 One way to report variations in FEV 1 is in relation to the predicted value: (postbronchodilator FEV 1 Ϫ prebronchodilator FEV 1 )/FEV 1 predicted. 24 This index has the advantage of being independent of the degree of initial obstruction, and the response is corrected for patient height, age, and sex. 8, 26, 27 Adopting an increase in FEV 1 percentage of predicted as the bronchodilator response criterion (⌬ Ͼ 10.3%), we were able to identify 37 patients with a significant response compared with a maximum of 34 patients when the increase in absolute volume was considered (⌬ Ͼ 265 mL). The increase in FEV 1 percentage of predicted is probably the best way to express this response in children, in addition to presenting better reproducibility in sequential tests performed on the same patient. 28 The measure of FVC variations did not have any additional advantage compared with criteria based on FEV 1 . The FVC is a useful tool when assessing patients with severe obstruction 24 and when the patients studied had mild obstructive ventilatory disturbances under baseline conditions.
Variations in FEF 25-75% after placebo inhalation did not have a normal distribution, as also observed by Sourk and Nugent. 17 In fact, the suitability of this parameter as a bronchodilator response criterion is questionable, and the ATS 10 itself does not recommend its use.
At baseline, the patients studied had on average signs of air trapping as determined by plethysmography, although spirometry demonstrated only mild obstruction. This finding is relevant to the prognosis of patients, because persistence of bronchial obstruction is believed to be associated with a reduction in lung elastic recoil, resulting in chronic air trapping and pulmonary hyperinflation. 19, 29, 30 In the present study, point assessment of the bronchodilator response revealed, on average, no modification in total lung capacity (TLC) or RV. Only long-term longitudinal studies will demonstrate whether the reduction in elastic recoil and the increase in residual functional capacity are temporary or represent primary signs of structural lesions. Measurement of lung volume might identify patients with a poor prognosis for whom both antiinflammatory and bronchodilator treatment should be optimized.
The present patients showed, on average, initial conductance values compatible with airway obstruction (0.11 L/s/cm H 2 O/L). The cutoff defined as a significant response was increased by 55% compared with the initial value, and this increase was much higher than those reported in the literature in which variations from 30 to 40% have already been considered to be significant. 6, 9, 31, 32 This difference in the bronchodilator response criterion might be explained by a wider variability of this parameter in the population studied due to its peculiar characteristics. Even when establishing a variation in conductance values higher than 55%, 48 patients (80%) were classified as responders, with this functional parameter thus being a sensitive index for the assessment of the bronchodilator response.
Conclusions
Comparison of the bronchodilator response criteria obtained in the present study with current international criteria demonstrated agreement for variations in FEV 1 expressed as absolute values and percentage of the predicted values. Plethysmography was the most sensitive test for the identification of changes in airway caliber. When assessing a population with peculiar characteristics, such as children and exclusively asthmatic patients, preference should be given to a response criterion derived from the group of patients itself.
